A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór (rak żołądka, połączenia żołądka z przełykiem lub przełyku) który można operacyjnie usunąć
- •W pierwszej grupie badania: pozytywny wynik na CLDN18.2 i brak HER2; w drugiej grupie: dodatni HER2
- •Ogólny stan zdrowia pozwalający na udział w badaniu (ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji nerek oraz wątroby
- •Waga powyżej 35 kg
✗ Disqualifies
- •Wcześniejsze chemioterapie lub operacje z powodu tego samego raka
- •Choroby autoimmunologiczne wymagające sterydów lub leków immunosupresyjnych
- •Przerzuty nowotworowe do odległych narządów
- •Aktywny wirus zapalenia wątroby typu B
- •Historia chorób płuc związanych z zapaleniem (bez względu na przyczynę)
- •Inny nowotwór w przeszłości
- •Niekontrolowane infekcje
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (70)
Research Site
Newark, United States
Research Site
Washington D.C., United States
Research Site
Fairway, United States
Research Site
North Shores, United States
Research Site
New York, United States
Research Site
New York, United States
Research Site
Pittsburgh, United States
Research Site
Toronto, Canada
Research Site
Montreal, Canada
Research Site
Montreal, Canada
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Changzhi, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Kunming, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shijiazhuang, China
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Tbilisi, Georgia
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Milan, Italy
Research Site
Modena, Italy
Research Site
Pisa, Italy
Research Site
Rozzano, Italy
Research Site
Udine, Italy
Research Site
Vicenza, Italy
Research Site
Chūōku, Japan
Research Site
Fukuoka, Japan
Research Site
Hidaka-shi, Japan
Research Site
Kashiwa, Japan
Research Site
Kitaadachi-gun, Japan
Research Site
Kōtoku, Japan
Research Site
Nagoya, Japan
Research Site
Osaka, Japan
Research Site
Osaka, Japan
Research Site
Suita-shi, Japan
Research Site
Yokohama, Japan
Research Site
Bialystok, Poland
Research Site
Warsaw, Poland
Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Elche, Spain
Research Site
Madrid, Spain
Research Site
Málaga, Spain
Research Site
Ourense, Spain
Research Site
Oviedo, Spain
Research Site
Santander, Spain
Research Site
Valencia, Spain
Research Site
Kaohsiung City, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan, Taiwan
Research Site
Adapazarı, Turkey (Türkiye)
Research Site
Erzurum, Turkey (Türkiye)
Research Site
Fatih-Istanbul, Turkey (Türkiye)
Research Site
Istanbul, Turkey (Türkiye)
Research Site
Bristol, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Headington, United Kingdom
Research Site
London, United Kingdom
Research Site
Norwich, United Kingdom
Trial contact
AstraZeneca Clinical Study Information Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.